Nucleai Partners with Protean BioDiagnostics to Improve Cancer Diagnosis

By CIOReview | Friday, May 10, 2019

Nucleai, a high-precision medicine artificial intelligence (AI) company, has partnered with Protean BioDiagnostics, a biotech company based in Tampa. They share a vision for the advancement of cancer diagnostic technology. Together they are coming up with the “Protean QA Service Enhancement powered by Nucleai." It's a co-branding program designed to synchronize the Nucleai’s AI-based services with advanced diagnostic tools of the Protean BioDiagnostic laboratories which will be utilized in labs, urology centers, and hospitals throughout the U.S.

Nucleai offers clinically oriented AI-based diagnosis and provides comprehensive AI- led solutions for biopsies including gastrointestinal, breast, and prostate tissue analysis as well as a pipeline to support additional indications.

Research suggests that a steep decline of up to 30 percent in the number of active pathologists in the U.S. is expected by 2030 owing to the advancement of AI-based diagnostic technologies. Protean BioDiagnostics is striving to ensure better diagnostic evaluation and partnering with Nucleai will allow it to access the most advanced AI-based technology supported by 20 million slides and 100 years of cumulative AI experience.

The Nucleai team is thrilled to partner with Protean BioDiagnostics, as both the companies have a shared vision of using AI for the improvement of cancer diagnostic purposes. Protean BioDiagnostics too takes pride in the collaboration and looks forward to the prospect of future endeavors with Nucleai. Both the companies anticipate advancement in precision medicine and will focus on working toward an advanced personalized oncology technology to help doctors and patients.

The experience of Protean BioDiagnostics on the molecular aspects of precision will enable Nuclei to develop an improved precision medicine solution and add it to the company’s technology platforms. With a track record to enhance efficiency and 97 percent reduced potential missed diagnoses, Nuclei’s collaboration with Protean BioDiagnostics holds a promising future for better diagnostics and reduced biopsy bottleneck.